Stockscreener 앱 받기
30.43
8.18%
-2.71
전일 마감가:
$33.14
열려 있는:
$33.91
하루 거래량:
1.88M
Relative Volume:
1.61
시가총액:
$2.52B
수익:
$352.57M
순이익/손실:
$-143.01M
주가수익비율:
-16.81
EPS:
-1.81
순현금흐름:
$-153.40M
1주 성능:
-6.08%
1개월 성능:
+24.05%
6개월 성능:
+19.38%
1년 성능:
-4.19%
1일 변동 폭
$30.19
$33.91
1주일 범위
$30.19
$35.25
52주 변동 폭
$20.84
$49.50
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
BEAM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
30.43 | 2.52B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-29 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-23 | 개시 | H.C. Wainwright | Buy |
| 2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 개시 | Citigroup | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-01-05 | 개시 | Guggenheim | Buy |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-09-24 | 재개 | Stifel | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Redburn | Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 개시 | Wells Fargo | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-08-05 | 개시 | William Blair | Outperform |
| 2020-03-02 | 개시 | Barclays | Overweight |
| 2020-03-02 | 개시 | JP Morgan | Overweight |
| 2020-03-02 | 개시 | Jefferies | Buy |
| 2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies - Benzinga India
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Takes $330,000 Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics (BEAM) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Cathie Wood’s ARK buys Beam Therapeutics, sells Adaptive Biotech stock By Investing.com - Investing.com Nigeria
Cathie Wood's ARK buys Beam Therapeutics, sells Adaptive Biotech stock - Investing.com India
Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Significant Decline in Short Interest - MarketBeat
Baillie Gifford & Co. Cuts Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Peregrine Investment Management Inc. Takes $3.93 Million Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 17.9%Here's What Happened - MarketBeat
Cathie Wood's ARK ETF adds Twist Bioscience, Beam Therapeutics stock By Investing.com - Investing.com Australia
Cathie Wood's ARK ETF adds Twist Bioscience, Beam Therapeutics stock - Investing.com
Cathie Wood’s ARK ETF adds Twist Bioscience, Beam Therapeutics stock By Investing.com - Investing.com Nigeria
Next Generation Genome Editing Market Top Companies Study - openPR
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Buys Shares of 13,287 Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics to present updated BEAM-101 trial data - MSN
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
(BEAM) Technical Data - Stock Traders Daily
Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday - Benzinga
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday - Benzinga
Wall Street Analysts See a 67.27% Upside in Beam Therapeutics (BEAM): Can the Stock Really Move This High? - Yahoo Finance
Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year? - MSN
Sumitomo Mitsui Trust Group Inc. Acquires 404,782 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics (BEAM) Stock Price, News & Analysis - MarketBeat
BMO Capital maintains Outperform on Beam Therapeutics stock By Investing.com - Investing.com Nigeria
BMO Capital maintains Outperform on Beam Therapeutics stock - MSN
Beam Therapeutics (NASDAQ:BEAM) Trading 8% HigherShould You Buy? - MarketBeat
FY2026 Earnings Estimate for BEAM Issued By HC Wainwright - MarketBeat
Brokers Issue Forecasts for BEAM Q1 Earnings - MarketBeat
HC Wainwright Reiterates "Buy" Rating for Beam Therapeutics (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) CEO Sells $802,500.00 in Stock - MarketBeat
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
빔 테라퓨틱스 주식 (BEAM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bellon Christine | Chief Legal Officer |
Feb 14 '25 |
Option Exercise |
7.22 |
10,000 |
72,200 |
112,968 |
| Bellon Christine | Chief Legal Officer |
Feb 14 '25 |
Sale |
34.00 |
10,000 |
340,000 |
102,968 |
0.27%
3.05%
자본화:
|
볼륨(24시간):